Friday, September 21, 2012
Medivir AB, of Huddinge, Sweden, said HCV NS3/4A protease inhibitor simeprevir (TMC435) and non-nucleoside inhibitor TMC647055 will enter a Phase IIa interferon-free combination trial for hepatitis C virus (HCV). The open-label trial will enroll about 40 patients chronically infected with HCV genotype-1a, and the primary endpoint will be sustained virologic response 12 weeks after the end of treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.